Chemistry:Navacaprant
From HandWiki
Navacaprant (developmental code names include BTRX-335140, BTRX-140, CYM-53093, NMRA-335140, and NMRA-140) is a selective κ-opioid receptor (KOR) antagonist which is under development for the treatment of major depressive disorder and bipolar depression.[1][2][3] It was originated by BlackThorn Therapeutics and is being developed by Neumora Therapeutics.[2] As of February 2025, navacaprant is in phase 3 clinical trials for major depressive disorder.[2][4] In January 2025, it was disclosed that navacaprant had failed to show effectiveness for major depressive disorder in a phase 3 trial.[5] Upon this announcement, the stock price of Neumora Therapeutics decreased by 80%.[5]
See also
- κ-Opioid receptor § Antagonists
- List of investigational antidepressants
- Aticaprant and icalcaprant
References
- ↑ "BlackThorn Therapeutics Advances Phase 2 Clinical Development for Selective KOR Antagonist, BTRX-140, in Neuropsychiatric Disorders" (in en). https://www.blackthornrx.com/publications/blackthorn-therapeutics-advances-phase-2-clinical-development-for-selective-kor-antagonist-btrx-140-in-neuropsychiatric-disorders/.
- ↑ 2.0 2.1 2.2 "BTRX 335140 - AdisInsight". https://adisinsight.springer.com/drugs/800054451.
- ↑ "Design and Synthesis of a Novel and Selective Kappa Opioid Receptor (KOR) Antagonist (BTRX-335140)". J. Med. Chem. 62 (4): 1761–1780. February 2019. doi:10.1021/acs.jmedchem.8b01679. PMID 30707578.
- ↑ Neumora Therapeutics, Inc. (2024-02-20). A Phase 3, Randomized, Double-blind, Placebo-controlled Study to Evaluate the Effects of Oral NMRA-335140 Versus Placebo in Participants With Major Depressive Disorder (Report). clinicaltrials.gov. https://clinicaltrials.gov/study/NCT06058039.
- ↑ 5.0 5.1 Taylor, Nick Paul (2 January 2025). "Neumora stumbles at start of phase 3 depression readout run, sending stock down 80%". https://www.fiercebiotech.com/biotech/neumora-stumbles-start-phase-3-depression-readout-run-sending-stock-down-80.
External links
 |  |
